Evercore ISI cuts Clorox stock price target on margin pressures By Investing.com

Clorox posted Q3 adjusted EPS of $1.64, beating the $1.55 consensus by $0.10, but management cut full-year FY2026 guidance to $5.45-$5.65 from $5.95-$6.30. Evercore ISI lowered its target to $110 from $115 and kept an Underperform rating, while Goldman Sachs cut its target to $83 from $94 with a Sell rating. The company also guided Q4 EPS to roughly $1.50-$1.70, with gross margin of 41%-42% versus the Street’s 46% forecast, signaling continued margin pressure.

Analysis

CLX looks less like a one-quarter miss and more like a transition into an earnings air pocket where reported numbers become noisier but economically weaker. The key second-order issue is that the company is entering a period where management can still cite transitory charges, yet the market will likely price the underlying demand trend first; that matters because staples multiple support depends on perceived pricing power, not just EPS stability. If scanner data is already only flattish while organic sales trail, then the problem is not temporary margin timing alone — it is that share gains and pricing are failing to offset category normalization.

The bigger tell is guidance compression happening before the full operating distortions hit. That tends to create a self-reinforcing de-rating: lower guidance reduces buy-side confidence, lower confidence suppresses inventory re-stocking and channel orders, and weaker orders then validate the cautious stance. In the next 1-2 quarters, any incremental bad news on gross margin from input costs or integration friction could force another reset, and the stock’s proximity to lows means there is still more downside if estimates continue to drift lower.

Contrarian angle: the market may already be over-penalizing the name for what is partly a calendar/timing problem, especially if the royalty benefit rolls off less abruptly than feared and the ERP disruption proves more “managed” than “messy.” But the burden of proof is now on management, not the stock. A sustainable rerating likely requires at least one quarter of visibly improving organic trends and margin stabilization; absent that, rallies should be treated as liquidity, not confirmation.

On GS, the read-through is modestly negative because consensus is still too willing to extrapolate stable consumer-packaged-goods fundamentals into a period of cost volatility and operational noise. GLAD is a relative winner only in the narrow sense that royalty tailwinds delay the clean comparison reset; that is not a durable benefit, just a timing cushion. The broader competitive implication is that smaller branded players with cleaner cost stacks may look better on a relative basis as CLX’s complexity rises, even if category demand itself is merely sluggish rather than collapsing.

Key Decisions for Investors

• Short CLX into any post-earnings stabilization bounce; 2-6 week horizon. Risk/reward favors downside if estimates keep drifting, with a tighter stop above the last analyst-target cluster near the low-$100s.
• Buy CLX put spreads 1-2 expiries out to express another guidance reset without paying for unlimited downside. Use a structure that targets a move back toward the low-90s if margin commentary worsens.
• Pair trade: long a cleaner household/personal care name with stronger organic momentum, short CLX, for the next 1-2 quarters. The trade is about execution dispersion, not category beta.
• Fade GS on consumer-staples operational weakness only as a tactical macro hedge, not a standalone short thesis. If Brent stays elevated, input-cost sensitivity can keep staple revision risk alive for several months.
• If CLX trades below recent lows without a fresh fundamental improvement, cover part of the short and wait for capitulation. The stock is close enough to value screens that a sentiment overshoot is possible, but only if forward estimate cuts stop.